mRNA Vaccines in Cancer Immunotherapy: Recent Advances, Clinical Translation, and Future Perspectives

Abstract

Cancer remains a leading global health burden. mRNA cancer vaccines, which are propelled by their rapid development, manufacturing flexibility, and proven efficacy against infectious diseases, have emerged as a transformative approach in cancer immunotherapy. While offering significant advantages over traditional methods, challenges related to mRNA instability and in vivo delivery efficiency persist. However, technological advancements, particularly in nanoparticle formulations such as lipid nanoparticles (LNPs), have substantially mitigated these concerns. This review comprehensively examines the mechanism of action of mRNA vaccines, focusing on their ability to encode tumor-specific antigens (TSAs), particularly neoantigens, and tumor-associated antigens (TAAs) to elicit potent anti-tumor immune responses. We critically analyzed the promising application of mRNA vaccines as monotherapies and, more significantly, in combination with immune checkpoint inhibitors, chemotherapy, adoptive cell therapies (e.g., CAR-T), and radiation to overcome the immunosuppressive tumor microenvironment. The core of this review synthesizes compelling results from key clinical trials across various cancers (e.g., melanoma, non-small cell lung cancer, and prostate cancer), highlighting significant outcomes such as induced neoantigen-specific T-cell responses, improved recurrence-free survival, and objective tumor regression. We also discuss the groundbreaking potential of personalized neoantigen mRNA vaccines. Current challenges, including tumor heterogeneity, optimal delivery strategies, biomarker identification, and enhancing therapeutic efficacy/safety profiles, are thoroughly evaluated alongside potential solutions. Finally, we explore future directions emphasizing next-generation approaches such as advanced nanovaccines and refined personalized platforms. This review aims to provide a timely and critical analysis of the rapidly evolving landscape of mRNA cancer vaccines, underscoring their immense potential to revolutionize cancer treatment paradigms.

Keywords

mRNA vaccine / Cancer vaccines / Cancer immunotherapy / Neoantigen / Lipid nanoparticles / Tumor microenvironment / Clinical trials / Therapeutic vaccine

References

[1] Ferlay J, Ervik M, Lam F, et al. Global Cancer Observatory: Cancer Today. Lyon (France): International Agency for Research on Cancer; 2024. Available from: https://gco.iarc.who.int/today. Accessed 4 Apr 2024.

[2] Sung H, Ferlay J, Siegel RL, et al.. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin., 2021, 71(3): 209-249

[3] Debela DT, Muzazu SG, Heraro KD, et al.. New approaches and procedures for cancer treatment: Current perspectives. SAGE Open Med., 2021, 9: 20503121211034366

[4] Twomey JD, Zhang B. Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics. AAPS J., 2021, 23: 39

[5] Braendstrup P, Levine BL, Ruella M. The long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19. Cytotherapy., 2020, 22(2): 57-69

[6] Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol., 2020, 20: 651-668

[7] Saxena M, van der Burg SH, Melief CJM, et al.. Therapeutic cancer vaccines. Nat Rev Cancer., 2021, 21: 360-378

[8] Lin MJ, Svensson-Arvelund J, Lubitz GS, et al.. Cancer vaccines: the next immunotherapy frontier. Nat Cancer., 2022, 3: 911-926

[9] Sobhani N, Scaggiante B, Morris R, et al.. Therapeutic cancer vaccines: From biological mechanisms and engineering to ongoing clinical trials. Cancer Treat Rev., 2022, 109102429

[10] Anassi E, Ndefo UA. Sipuleucel-T (provenge) injection: the first immunotherapy agent (vaccine) for hormone-refractory prostate cancer. P T., 2011, 36(4197-202

[11] Miao L, Zhang Y, Huang L. mRNA vaccine for cancer immunotherapy. Mol Cancer., 2021, 20(1): 41

[12] Wang B, Pei J, Xu S, et al.. Recent advances in mRNA cancer vaccines: meeting challenges and embracing opportunities. Front Immunol., 2023, 14: 1246682

[13] Martinon F, Krishnan S, Lenzen G, et al.. Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome-entrapped mRNA. Eur J Immunol., 1993, 23(71719-1722

[14] Wittrup A, Lieberman J. Knocking down disease: A progress report on siRNA therapeutics. Nat Rev Genet., 2015, 16(9543-552

[15] Hanson G, Coller J. Translation and Protein Quality Control: Codon optimality, bias and usage in translation and mRNA decay. Nat Rev Mol Cell Biol., 2018, 19(1): 20-30

[16] Yoshida T, Mei H, Dörner T, et al.. Memory B and memory plasma cells. Immunol Rev., 2010, 237(1): 117-139

[17] Sahin U, Karikó K, Türeci Ö. mRNA-based therapeutics-developing a new class of drugs. Nat Rev Drug Discov., 2014, 13(10): 759-780

[18] Rosa SS, Prazeres DMF, Azevedo AM, et al.. mRNA vaccines manufacturing: Challenges and bottlenecks. Vaccine., 2021, 39(16): 2190-2200

[19] El-Malky AM, Al-Kathiri WH, El Nouman AA. When shall coronavirus disease-19 stop? Review of literature. Open Access Maced J Med Sci., 2020, 8(T1): 75-81

[20] Pollard C, De Koker S, Saelens X, et al.. Challenges and advances towards the rational design of mRNA vaccines. Trends Mol Med., 2013, 19(12): 705-713

[21] Zhang Y, Xiao Y, Sun G, et al.. Harnessing the therapeutic potential of extracellular vesicles for cancer treatment. Semin Cancer Biol., 2021, 74: 92-104

[22] Lang F, Schrörs B, Löwer M, et al.. Identification of neoantigens for individualized therapeutic cancer vaccines. Nat Rev Drug Discov., 2022, 21(4): 261-282

[23] Blass E, Ott PA. Advances in the development of personalized neoantigen-based therapeutic cancer vaccines. Nat Rev Clin Oncol., 2021, 18(4): 215-229

[24] Mollica Poeta V, Massara M, Capucetti A, et al.. Chemokines and chemokine receptors: new targets for cancer immunotherapy. Front Immunol., 2019, 10: 379

[25] Harper DM, Franco EL, Wheeler C, et al.. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet., 2004, 364(9447): 1757-1765

[26] McAleer WJ, Buynak EB, Maigetter RZ, et al.. Human hepatitis B vaccine from recombinant yeast. Nature., 1984, 307(5947178-180

[27] Ott PA, Hu Z, Keskin DB, et al.. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature., 2017, 547(7662): 217-221

[28] Keskin DB, Anandappa AJ, Sun J, et al.. Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature., 2019, 565(7738): 234-239

[29] Singh P, Khatib MN, Roopashree R, et al.. Advancements and challenges in personalized neoantigen-based cancer vaccines. Oncol Rev., 2025, 19: 1541326

[30] Hu Z, Leet DE, Allesøe RL, et al.. Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma. Nat Med., 2021, 27(3): 515-525

[31] Sethna Z, Guasp P, Reiche C, et al.. RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer. Nature., 2025, 639(80561042-1051

[32] Roma-Rodrigues C, Raposo LR, Cabral R, et al.. Tumor microenvironment modulation via gold nanoparticles targeting malicious exosomes: Implications for cancer diagnostics and therapy. Int J Mol Sci., 2017, 18(1): E162

[33] Melief CJM, Van Hall T, Arens R, et al.. Therapeutic cancer vaccines. J Clin Invest., 2015, 125(93401-3412

[34] Giannakis M, Mu XJ, Shukla SA, et al.. Genomic correlates of immune-cell infiltrates in colorectal carcinoma. Cell Rep., 2016, 15(4): 857-865

[35] Hollingsworth RE, Jansen K. Turning the corner on therapeutic cancer vaccines. NPJ Vaccines., 2019, 4: 7

[36] Kwak M, Leick KM, Melssen MM, et al.. Vaccine strategy in melanoma. Surg Oncol Clin N Am., 2019, 28(3): 337-351

[37] Utsugi-Kobukai S, Fujimaki H, Hotta C, et al.. MHC class I-mediated exogenous antigen presentation by exosomes secreted from immature and mature bone marrow-derived dendritic cells. Immunol Lett., 2003, 89(2–3125-131

[38] Yang Y. Cancer immunotherapy: harnessing the immune system to battle cancer. J Clin Invest., 2015, 125(9): 3335-3337

[39] Sahin U, Derhovanessian E, Miller M, et al.. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature., 2017, 547(7662): 222-226

[40] Kreiter S, Vormehr M, van de Roemer N, et al.. Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature., 2015, 520(7549): 692-696

[41] Kang J, Demaria S, Formenti SC. Current clinical trials testing the combination of immunotherapy with radiotherapy. J Immunother Cancer., 2016, 4: 51

[42] Papachristofilou A, Hipp MM, Klinkhardt U, et al.. Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer. J Immunother Cancer., 2019, 7(1): 68

[43] Krug C, Wiesinger M, Abken H, et al.. A GMP-compliant protocol to expand and transfect cancer patient T cells with mRNA encoding a tumor-specific chimeric antigen receptor. Cancer Immunol Immunother., 2014, 63(10999-1008

[44] Kuhn AN, Diken M, Kreiter S, et al.. Phosphorothioate cap analogs increase stability and translational efficiency of RNA vaccines in immature dendritic cells and induce superior immune responses in vivo. Gene Ther., 2010, 17(8961-971

[45] Dolgin E. The tangled history of mRNA vaccines. Nature., 2021, 597(7876): 318-324

[46] Vishweshwaraiah YL, Dokholyan NV. mRNA vaccines for cancer immunotherapy. Front Immunol., 2022, 13: 1029069

[47] Sahin U, Oehm P, Derhovanessian E, et al.. An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma. Nature., 2020, 585(7823): 107-112

[48] Ahern E, Solomon BJ, Hui R, et al. A phase I study (E011-MEL) of a TriMix-based mRNA immunotherapy (ECI-006) in resected melanoma patients: Analysis of safety and immunogenicity. J Clin Oncol. 2019;37(15_suppl):2641.

[49] Magoola M, Niazi SK. Current progress and future perspectives of RNA-based cancer vaccines: A 2025 Update. Cancers (Basel)., 2025, 17(111882

[50] Mackensen A, Haanen JBAG, Koenecke C, et al.. CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial. Nat Med., 2023, 29(112844-2853

[51] Cafri G, Gartner JJ, Zaks T, et al.. mRNA vaccine–induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer. J Clin Invest., 2020, 130(11): 5976-5988

[52] Burris HA, Patel MR, Cho DC, et al. A phase I multicenter study to assess the safety, tolerability, and immunogenicity of mRNA-4157 alone in patients with resected solid tumors and combination with pembrolizumab in patients with unresectable solid tumors. J Clin Oncol. 2019;37(15_suppl):2523.

[53] Sequist LV, Yang JC-H, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013;31(27):3327–3334.

[54] Weber JS, Carlino MS, Khattak A, et al.. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. Lancet., 2024, 403(10427): 632-644

[55] Long GV, Luke JJ, Khattak MA, et al.. Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial. Lancet Oncol., 2022, 23(11): 1378-1388

[56] Tan T, Deng ST, Wu BH, et al.. mRNA Vaccine - A New Cancer Treatment Strategy. Curr Cancer Drug Targets., 2023, 23(2): 121-132

[57] Yao R, Xie C, Xia X. Recent progress in mRNA cancer vaccines. Hum Vaccin Immunother., 2024, 20(1e2307187

[58] Stratton MR. Exploring the genomes of cancer cells: progress and promise. Science., 2011, 331(6024): 1553-1558

[59] Bolli N, Avet-Loiseau H, Wedge DC, et al.. Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nat Commun., 2014, 5: 2997

[60] Titmuss E, Milne K, Jones MR, et al.. Response to angiotensin blockade with irbesartan in a patient with metastatic colorectal cancer. Ann Oncol., 2016, 27(4): 725-726

[61] Rupaimoole R, Calin GA, Lopez-Berestein G, et al.. miRNA Deregulation in Cancer Cells and the Tumor Microenvironment. Cancer Discov., 2016, 6(3235-246

[62] Lorentzen CL, Haanen JB, Met Ö, et al.. Clinical advances and ongoing trials of mRNA vaccines for cancer treatment. Lancet Oncol., 2022, 23(10): e450-e458

[63] Iinuma H, Fukushima R, Inaba T, et al.. Phase I clinical study of multiple epitope peptide vaccine combined with chemoradiation therapy in esophageal cancer patient. J Transl Med., 2014, 12: 84

[64] Heine A, Juranek S, Brossart P. Clinical and immunological effects of mRNA vaccine in malignant diseases. Mol Cancer., 2021, 20(1): 83

[65] Sayour EJ, De Leon G, Pham C, et al.. Systemic activation of antigen-presenting cells via RNA-loaded nanoparticles. Oncoimmunology., 2017, 6(2e1256527

[66] Pardi N, Hogan MJ, Weissman D. Recent advances in mRNA vaccine technology. Curr Opin Immunol., 2020, 65: 14-20

[67] Caushi JX, Smith KN. Quantifying the anti-tumor immune response in patients receiving immunotherapy. Discov Med., 2017, 23(125221-229

[68] Li Y, Wang M, Peng X, et al.. mRNA vaccine in cancer therapy: current advance and future outlook. Clin Transl Med., 2023, 13(6e1384

[69] Linares-Fernández S, Lacroix C. Tailoring mRNA vaccine to balance innate/adaptive immune response. Trends Mol Med., 2019, 25(12): 1013-1024

[70] De Beuckelaer A, Grooten J, De Koker S. Type I interferons modulate CD8+ T cell immunity to mRNA vaccines. Trends Mol Med., 2017, 23(3): 216-226

[71] Wahane A, Waghmode A, Kapphahn A, et al.. Role of lipid-based and polymer-based non-viral vectors in nucleic acid delivery for next-generation gene therapy. Molecules., 2020, 25(12): 2866

[72] Hewitt SL, Bai A, Bailey D, et al. Durable anti-cancer immunity from intratumoral administration of IL-23, IL-36γ, and OX40L mRNAs. Sci Transl Med. 2019;11(477):eaat 9143.

[73] McKinlay CJ, Benner NL, Haabeth OA, et al.. Enhanced mRNA delivery into lymphocytes enabled by lipid-varied libraries of charge-altering releasable transporters. Proc Natl Acad Sci U S A., 2018, 115(26E5859-E5866

[74] Haabeth OAW, Blake TR, McKinlay CJ, et al.. mRNA vaccination with charge-altering releasable transporters elicits human T cell responses and cures established tumors in mice. Proc Natl Acad Sci U S A., 2018, 115(28): E6404-E6413

[75] Coolen AL, Lacroix C, Mercier-Gouy P, et al.. Poly (lactic acid) nanoparticles and cell-penetrating peptide potentiate mRNA-based vaccine expression in dendritic cells triggering their activation. Biomaterials., 2019, 195: 23-35

[76] McCullough KC, Milona P, Thomann-Harwood L, et al.. Self-amplifying replicon RNA vaccine delivery to dendritic cells by synthetic nanoparticles. Vaccines (Basel)., 2014, 2(4): 735-754

[77] Xu J, Luft JC, Yi X, et al.. RNA replicon delivery via lipid-complexed PRINT protein particles. Mol Pharm., 2013, 10(9): 3366-3374

[78] Esprit A, de Mey W, Bahadur Shahi R, et al.. Neo-antigen mRNA vaccines. Vaccines (Basel)., 2020, 8(4): 776

[79] Wirth TC, Kühnel F. Neoantigen targeting—dawn of a new era in cancer immunotherapy?. Front Immunol., 2017, 8: 1848

[80] Shemesh CS, Hsu JC, Hosseini I, et al.. Personalized cancer vaccines: clinical landscape, challenges, and opportunities. Mol Ther., 2021, 29(2555-570

[81] Chehelgerdi M, Chehelgerdi M. The use of RNA-based treatments in the field of cancer immunotherapy. Mol Cancer., 2023, 22(1106

[82] Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines—a new era in vaccinology. Nat Rev Drug Discov., 2018, 17(4261-279

[83] Chen S, Huang X, Xue Y, et al.. Nanotechnology-based mRNA vaccines. Nat Rev Methods Primers., 2023, 3: 63

[84] Huang T, Peng L, Han Y, et al.. Lipid nanoparticle-based mRNA vaccines in cancers: current advances and prospects. Front Immunol., 2022, 13922301

[85] Fang X, Lan H, Jin K, et al.. Nanovaccines for cancer prevention and immunotherapy: an update review. Cancers (Basel)., 2022, 14(16): 3842

[86] Türeci Ö, Vormehr M, Diken M, et al.. Targeting the heterogeneity of cancer with individualized neoepitope vaccines. Clin Cancer Res., 2016, 22(81885-1896

[87] Rojas LA, Sethna Z, Soares KC, et al.. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature., 2023, 618(7965144-150

RIGHTS & PERMISSIONS

The Author(s), under exclusive licence to the Huazhong University of Science and Technology